Safety and Tolerability of Tegaserod for Irritable Bowel Syndrome

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Tegaserod is a unique agent that provides global relief of the multiple symptoms of IBS in patients with IBS-C. More than 6,000 patients received tegaserod in short-term (at least eight-week) clinical studies, and many of these patients have remained on therapy for six months (n = 1,200) or 12 months (n = 508). ADEs that were associated with tegaserod in these studies were generally mild and transient in nature. Animal and human studies indicate that tegaserod is not associated with adverse cardiovascular events. A close examination of abdominal surgery data indicates that the use of tegaserod is not associated with increased rates of such procedures. Furthermore, this medication does not appear to alter metabolism significantly, compared with other medications. Tegaserod has received marketing approval in more than 45 countries. In the U.S., more than 350,000 prescriptions have been filled since the FDA's approval in July 2002. Post-marketing safety assessments are being conducted.

Original languageEnglish (US)
Pages (from-to)174-183
Number of pages10
JournalP and T
Volume29
Issue number3
StatePublished - Mar 1 2004

Fingerprint

Irritable Bowel Syndrome
Safety
Marketing
Prescriptions
tegaserod

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Safety and Tolerability of Tegaserod for Irritable Bowel Syndrome. / Howden, Colin.

In: P and T, Vol. 29, No. 3, 01.03.2004, p. 174-183.

Research output: Contribution to journalReview article

@article{e378bcadbd054608be1ab1ea8aef4833,
title = "Safety and Tolerability of Tegaserod for Irritable Bowel Syndrome",
abstract = "Tegaserod is a unique agent that provides global relief of the multiple symptoms of IBS in patients with IBS-C. More than 6,000 patients received tegaserod in short-term (at least eight-week) clinical studies, and many of these patients have remained on therapy for six months (n = 1,200) or 12 months (n = 508). ADEs that were associated with tegaserod in these studies were generally mild and transient in nature. Animal and human studies indicate that tegaserod is not associated with adverse cardiovascular events. A close examination of abdominal surgery data indicates that the use of tegaserod is not associated with increased rates of such procedures. Furthermore, this medication does not appear to alter metabolism significantly, compared with other medications. Tegaserod has received marketing approval in more than 45 countries. In the U.S., more than 350,000 prescriptions have been filled since the FDA's approval in July 2002. Post-marketing safety assessments are being conducted.",
author = "Colin Howden",
year = "2004",
month = "3",
day = "1",
language = "English (US)",
volume = "29",
pages = "174--183",
journal = "P and T",
issn = "1052-1372",
publisher = "MediMedia USA Inc.",
number = "3",

}

TY - JOUR

T1 - Safety and Tolerability of Tegaserod for Irritable Bowel Syndrome

AU - Howden, Colin

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Tegaserod is a unique agent that provides global relief of the multiple symptoms of IBS in patients with IBS-C. More than 6,000 patients received tegaserod in short-term (at least eight-week) clinical studies, and many of these patients have remained on therapy for six months (n = 1,200) or 12 months (n = 508). ADEs that were associated with tegaserod in these studies were generally mild and transient in nature. Animal and human studies indicate that tegaserod is not associated with adverse cardiovascular events. A close examination of abdominal surgery data indicates that the use of tegaserod is not associated with increased rates of such procedures. Furthermore, this medication does not appear to alter metabolism significantly, compared with other medications. Tegaserod has received marketing approval in more than 45 countries. In the U.S., more than 350,000 prescriptions have been filled since the FDA's approval in July 2002. Post-marketing safety assessments are being conducted.

AB - Tegaserod is a unique agent that provides global relief of the multiple symptoms of IBS in patients with IBS-C. More than 6,000 patients received tegaserod in short-term (at least eight-week) clinical studies, and many of these patients have remained on therapy for six months (n = 1,200) or 12 months (n = 508). ADEs that were associated with tegaserod in these studies were generally mild and transient in nature. Animal and human studies indicate that tegaserod is not associated with adverse cardiovascular events. A close examination of abdominal surgery data indicates that the use of tegaserod is not associated with increased rates of such procedures. Furthermore, this medication does not appear to alter metabolism significantly, compared with other medications. Tegaserod has received marketing approval in more than 45 countries. In the U.S., more than 350,000 prescriptions have been filled since the FDA's approval in July 2002. Post-marketing safety assessments are being conducted.

UR - http://www.scopus.com/inward/record.url?scp=1642564351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642564351&partnerID=8YFLogxK

M3 - Review article

VL - 29

SP - 174

EP - 183

JO - P and T

JF - P and T

SN - 1052-1372

IS - 3

ER -